Clinical Trial Update: 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing the safety of HMR1964 with insulin aspart in continuous subcutaneous infusion for Type 1 diabetes has completed. The sponsor is Sanofi.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• HMR1964 (HMR1964)
• Insulin aspart (insulin aspart)

Snippet

Sponsor: Sanofi | Conditions: Diabetes, Type I | Phase 3 | Status: COMPLETED